Tetsuhiko Shirasaka
Minato, 1088641, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.
Journal: Cancer chemotherapy and pharmacology
Published: January 12, 2017
Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).
Journal: International journal of clinical oncology
Published: October 31, 2016
Evolving 5-Fluorouracil Therapy to Achieve Enhanced Efficacy-Past and Current Efforts of Researchers
Evolving 5-Fluorouracil Therapy to Achieve Enhanced Efficacy-Past and Current Efforts of Researchers
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: July 20, 2016
Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration.
Journal: International journal of clinical oncology
Published: November 05, 2014
Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects.
Journal: International journal of clinical oncology
Published: September 25, 2013
Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer.
Journal: Cancer chemotherapy and pharmacology
Published: May 26, 2013
A case of successful S-1 alternate-day administration for far-advanced remnant gastric cancer
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: March 17, 2012
S-1 as a core anticancer fluoropyrimidine agent.
Journal: Expert opinion on drug delivery
Published: January 13, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026